FDA misses PDUFA review deadline for Agios' thalassemia drug
FDA misses PDUFA review deadline for Agios' thalassemia drug
Body unavailable. Use the original source.
FDA misses PDUFA review deadline for Agios' thalassemia drug
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.